Is there a role for myeloablative chemotherapy with autologous hematopoietic cell rescue in the management of childhood high-grade astrocytomas?

Maura Massimino, Kenneth J. Cohen, Jonathan L. Finlay

Research output: Contribution to journalReview articlepeer-review

Abstract

High-grade or malignant glioma represent 10% of pediatric brain tumors and are, taken as a whole, the second more frequent malignant histotype after medulloblastoma. Apart from a complete excision followed by full dose local radiotherapy, chemotherapy seems to give some beneficial to final outcome. Different trials have explored the role of high-dose chemotherapy that theoretically could give an advantage to these patients by overcoming blood-brain barrier, tumor cell chemo-resistance and inducing a wider number of responses. It is, however, still doubtful if better responses translate into improved outcome and which patients can have a true beneficial from this treatment strategy.

Original languageEnglish (US)
Pages (from-to)641-643
Number of pages3
JournalPediatric Blood and Cancer
Volume54
Issue number4
DOIs
StatePublished - Apr 2010

Keywords

  • Anaplastic glioma
  • Blood-brain barrier
  • Glioblastoma
  • High-dose chemotherapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Is there a role for myeloablative chemotherapy with autologous hematopoietic cell rescue in the management of childhood high-grade astrocytomas?'. Together they form a unique fingerprint.

Cite this